These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24944077)

  • 1. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
    Ziauddin MF; Hua D; Tang SC
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
    Provenzano A; Kurian S; Abraham J
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies in estrogen receptor-positive breast cancer.
    Johnston SR
    Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
    Johnston SR
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
    Nagaraj G; Ma C
    Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
    Moy B; Goss PE
    Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to endocrine therapy in breast cancer.
    Kurebayashi J
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.